VoxelWAR:VOX +1.98%95 EBITDA Margin % is 33.95% as of Mar. 2026, which is 19% above its 10-year median of 28.45. GuruFocus rates WAR:VOX with a GF Score™ of 95/100 and a GF Value™ of zł131.15 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Voxel ranks better than 95.07% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Voxel's EBITDA for the
three
months ended in Mar. 2026 was zł53.4 Mil. Voxel's Revenue for the
three
months ended in Mar. 2026 was zł157.2 Mil. Therefore, Voxel's EBITDA margin for the quarter that ended in Mar. 2026 was 33.95%.
Voxel (WAR:VOX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Voxel EBITDA Margin % Related Terms
Voxel EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Voxel's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:VOX vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Voxel's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voxel EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Voxel's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Voxel's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voxel (WAR:VOX) has a EBITDA Margin % of 33.95% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Voxel and its competitors. This is 19% above median its historical median of 28.45. Over the past decade, Voxel's EBITDA Margin % has ranged from 24.78 to 35.71. According to the industry distribution chart, Voxel ranks #10 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 4.9%.
Is Voxel's EBITDA Margin % too high?
Voxel's current EBITDA Margin % of 33.95% is 19% above median its 10-year median of 28.45. Over the past 10 years, this metric has ranged from a low of 24.78 to a high of 35.71. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Voxel's value of 33.95% is 579% above this industry median. Based on the distribution chart, Voxel ranks #10 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Voxel has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Voxel's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Voxel ranks #10 out of 203 companies for EBITDA Margin %. This places Voxel in the top 5% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.00. Voxel's value of 33.95% is 579% above this benchmark. Historically, Voxel's own EBITDA Margin % has ranged from 24.78 to 35.71 over the past decade. While the company's 10-year median is 28.45 vs. the industry median of 5.00, Voxel has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Voxel's current EBITDA Margin % of 33.95% is 579% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Voxel and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voxel's current EBITDA Margin % is 33.95%, which is 19% above median its own 10-year median of 28.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voxel stock overvalued right now?
Based on GuruFocus' analysis, Voxel (WAR:VOX) is currently considered Modestly Undervalued. The stock's GF Value™ is zł131.15, compared to a current price of zł113.20 — trading 13.7% below its estimated fair value. The current EBITDA Margin % is 33.95%, which is 19% above median its 10-year median of 28.45 and 579% above the Medical Diagnostics & Research industry median of 5.00. Voxel's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Voxel (WAR:VOX), the current EBITDA Margin % is 33.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voxel (WAR:VOX) Overvalued in 2026?
Based on GuruFocus' analysis, Voxel stock appears to be undervalued.
The current stock price of zł113.20 is trading 13.7% below its estimated GF Value™ of zł131.15.
GuruFocus considers Voxel to be Modestly Undervalued.
Key valuation signals for WAR:VOX:
EBITDA Margin %: 33.95% (19% above median its 10-year median of 28.45)
GF Value™: zł131.15 vs. price of zł113.20 (13.7% below fair value)
Industry Position: 579% above the Medical Diagnostics & Research median (#10 of 203)
No single metric tells the full story. See the WAR:VOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voxel SA is a network of diagnostic imaging laboratories created for patients and to increase access to high-quality tests. The company operates diagnostic imaging centers and laboratories and provides several services such as magnetic resonance imaging, computed tomography and positron emission tomography. It has 33 specialised laboratories in 21 cities throughout Poland.
95GF Score
Get the complete analysis for WAR:VOX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:VOX has been successfully added to your 
